Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTM-H-001 in B-Cell-Related Autoimmune Diseases
NCT07593911Not yet recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Jun 2026
- Primary completion
- Nov 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of MTM-H-001 in systemic lupus erythematosus (SLE), lupus nephritis (LN), multiple sclerosis (MS) and 3 more, sponsored by Beijing Gaobo Hospital. Primary endpoint: Incidence of Dose-Limiting Toxicity at 42 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
MTM-H-001
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)multiple sclerosis (MS)myasthenia gravis (MG)IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07593911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593911.